Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Peter Clark, MA, MD, FRCP: A Payer Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Dec
16
Today In Oncology
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Menopausal Hormone Therapy Not Associated With Increased Breast Cancer Risk
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications
FDA Approves Regimen for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo